BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) announced today that scientists from the company will present results of two preclinical studies with sapacitabine and seliciclib, the company’s most advanced drug candidates in clinical development. The results will be reported in two poster presentations during the upcoming Annual Meeting of the American Association for Cancer Research (AACR) taking place at the Los Angeles Convention Center between April 14-18, 2007. Sapacitabine is an orally-available, novel nucleoside analog in Phase I clinical trials in patients with solid and hematological cancers. Seliciclib is the most advanced orally-available, cyclin dependent kinase (CDK) inhibitor in Phase II clinical development in patients with non-small cell lung cancer. Sapacitabine and seliciclib are the lead drug candidates in Cyclacel’s pipeline of small molecule cell cycle inhibitors.
